Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Timing in Stage I-II NSCLC (IFCT-0002)
NCT00198354Phase 3Completed
- Sponsor
- IFCT
- Start
- May 2001
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) (4 arms), sponsored by IFCT. Primary endpoint: Overall Survival at 3 years. Started May 2001; status: completed.
02
Drugs
gemcitabinecisplatinpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00198354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198354.